chrysalis_top_new
chrysalis_top_new
Slide 2
Slide 2
Slide 3
Slide 3
Slide 4
Slide 4

The Chrysalin® Solution for Nuclear Emergencies

With the recent radiation release from reactors in Japan and increased potential of a nuclear “dirty bomb” detonation somewhere in the world, there is an immediate need to establish an emergency stockpile of safe and effective medicinal countermeasures to mitigate effects of nuclear radiation. It is estimated that hundreds of thousands of people could die following a nuclear detonation in any major city from radiation exposure alone or from the combined effects of radiation and injuries. A number of studies have shown that the combination of radiation exposure and injury increases mortality. Thus, we need countermeasures that also can prevent mortality caused by radiation exposure combined with dermal injuries, burns, fractures, and surgical procedures.

Preclinical studies demonstrate that TP508 significantly increases survival of animals when administered up to 28 hours after exposure to nuclear radiation combined with a dermal injury. In these studies, radiation also delays the healing of the dermal wounds, but TP508 treatment causes wounds to heal at a rate similar to wounds in normal animals that are not exposed to radiation. Thus, TP508 treatment accelerates healing and at the same time increases survival. This indicates that TP508 treatment will save the lives of thousands of individuals exposed to nuclear radiation or radiation combined with injury.

Recent preclinical studies also have shown that even at higher doses of nuclear radiation where exposure leads to nearly 100% mortality within two weeks, TP508 post exposure injection delays events leading to death and increases the probability of survival. Thousands of individuals exposed to high doses of radiation will require in-hospital blood transfusions and advanced care. However, following a nuclear explosion it may take days to transport these individuals to hospitals for advanced treatment. The present data suggests that using TP508 as a field-delivered preventive therapy could delay mortality even in individuals exposed to high levels of radiation, giving emergency personnel additional time to transport these victims to locations where they can receive blood transfusions and other life-saving therapies.

Chrysalis BioTherapeutics, Inc., is committed to helping improve people's lives through innovation.
Skip to toolbar